Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

A global international trial of an mRNA vaccine against norovirus is getting underway with the aim of reducing the health burden caused by the infamous “winter vomiting” bug. The trial has been ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The pharmaceutical sector continues to attract investor attention, with recent clinical developments highlighting the industry’s innovation potential. Moderna (MRNA) emerged as the top-performing ...

In the latest close session, Moderna (MRNA) was down 1.48% at $47.99. The stock fell short of the S&P 500, which registered a gain of 0.5% for the day. Elsewhere, the Dow gained 0.64%, while the ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US administration. Yet amid the defunding and hostile public opinion, Chris Baraniuk ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...